Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIB1116 in rheumatic diseases
NCT04948099Phase 1Completed
- Sponsor
- Amgen
- Start
- Jul 2021
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in Rheumatic diseases comparing VIB1116 with Placebo (2 arms). Primary endpoint: Treatment-emergent adverse events. Started Jul 2021; status: completed.
02
Drugs
VIB-1116
03
Conditions
Rheumatic diseases
Beyond the preview
Go deeper on NCT04948099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04948099.